JPMorgan Chase & Co. Raises Natera (NASDAQ:NTRA) Price Target to $360.00

Key Points

• JPMorgan raised Natera’s price target to $360 from $315 and maintained an “overweight” rating, implying 14.91% upside from the previous close.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and average price target of $296.74, supported by several recent target increases from major firms.
• Natera reported second-quarter revenue of $752.8 million, up 37.7% year over year and above estimates, while its adjusted loss per share was slightly better than expected; management projects approximately $2.9 billion in fiscal 2026 revenue.

Natera (NASDAQ:NTRA - Get Free Report) had its price target boosted by analysts at JPMorgan Chase & Co. from $315.00 to $360.00 in a research report issued on Friday,Benzinga reports. The firm presently has an "overweight" rating on the medical research company's stock. JPMorgan Chase & Co.'s target price suggests a potential upside of 14.91% from the stock's previous close.

Other equities research analysts have also recently issued reports about the company. Piper Sandler restated an "overweight" rating and issued a $249.00 price objective on shares of Natera in a research note on Tuesday, May 12th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $350.00 target price on shares of Natera in a research note on Friday. Guggenheim upped their price target on shares of Natera from $270.00 to $290.00 and gave the company a "buy" rating in a research note on Monday, June 29th. Wall Street Zen cut shares of Natera from a "buy" rating to a "hold" rating in a research note on Saturday, May 9th. Finally, Morgan Stanley boosted their price objective on shares of Natera from $250.00 to $310.00 and gave the stock an "overweight" rating in a research note on Thursday, July 9th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $296.74.

Natera Stock Performance

NASDAQ NTRA traded up $47.91 on Friday, hitting $313.30. 1,581,004 shares of the stock traded hands, compared to its average volume of 1,349,040. The business's fifty day moving average is $252.06 and its two-hundred day moving average is $223.09. Natera has a 12 month low of $149.38 and a 12 month high of $322.00. The firm has a market capitalization of $44.87 billion, a price-to-earnings ratio of -192.83 and a beta of 1.51.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Friday, August 7th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.The firm had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same period in the previous year, the company posted ($0.74) earnings per share. The business's revenue was up 37.7% on a year-over-year basis. Analysts expect that Natera will post -1.49 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Michael Burkes Brophy sold 478 shares of the business's stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total value of $131,077.16. Following the completion of the transaction, the chief financial officer owned 51,637 shares of the company's stock, valued at $14,159,898.14. The trade was a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the sale, the insider directly owned 129,019 shares in the company, valued at $34,264,866.02. This trade represents a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 181,045 shares of company stock valued at $41,330,968 in the last three months. 5.05% of the stock is owned by company insiders.

Hedge Funds Weigh In On Natera

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Coatue Management LLC lifted its holdings in Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock valued at $603,270,000 after acquiring an additional 2,463,008 shares during the period. Wellington Management Group LLP grew its stake in Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares in the last quarter. Norges Bank purchased a new stake in Natera during the 4th quarter worth about $372,398,000. JPMorgan Chase & Co. boosted its stake in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock valued at $2,944,800,000 after buying an additional 1,225,420 shares during the period. Finally, AQR Capital Management LLC grew its position in shares of Natera by 39.0% during the third quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company's stock worth $386,338,000 after buying an additional 673,315 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera reported second-quarter revenue of $752.8 million, up 37.7% year over year and well above the $661.2 million analyst consensus. The company’s adjusted loss of $0.47 per share was slightly better than the expected $0.49 loss and improved from a $0.74 loss a year earlier. Gross margin also increased to 64.5% from 63.4%. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised or reaffirmed its fiscal 2026 revenue outlook at approximately $2.9 billion, above the roughly $2.8 billion consensus estimate. The stronger outlook suggests continued momentum across Natera’s reproductive health, oncology and transplant-testing franchises.
• Positive Sentiment: Natera submitted its Signatera molecular residual disease test to Japan’s Pharmaceuticals and Medical Devices Agency for approval as a companion diagnostic in muscle-invasive bladder cancer. Regulatory approval could expand Signatera’s international market opportunity and create a future source of revenue growth. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: The earnings call provided additional management commentary on the quarter and outlook. Investors are likely focused on whether rapid revenue growth can continue while Natera improves profitability.
• Neutral Sentiment: The CEO, CFO and other executives sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding tied to vested equity awards. The transactions totaled roughly 7,576 shares, but the executives retained substantial holdings, limiting their significance as a negative confidence signal.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source